Monoclonal antibodies in the treatment of steroid resistant acute graft- versus-host disease

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 988-1000

  Tse, John C ^a   Moore, Theodore B ^b  

^a UCLA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE ANTIBODY; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; POLYCLONAL ANTIBODY; STEROID; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE ANTIGEN; THYMOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; CHILL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESPONSE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HYBRIDOMA; HYPOTENSION; LEUKOPENIA; PATHOPHYSIOLOGY; RELAPSE; REVIEW; SURVIVAL; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0031711469     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Gatti RA, Meuwissen HF, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366-9.
2. Thomas ED. Bone marrow transplantation: past experiences and future prospects. Semin Oncol 1992;19(3, suppl 7):3-6.
3. Appelbaum FR, Dahlberg S, Thomas ED, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. Ann Intern Med 1984;101:581-8.
4. Blume KG, Beutler E, Bross KJ, et al. Bone marrow ablation and allogeneic marrow transplantation in leukemia. N Engl J Med 1980;302:1041-6.
5. Blume KG, Forman SJ, Snyder DS, et al. Allogeneic bone marrow transplantation for the acute lymphoblastic leukemia during first complete remission. Transplantation 1987;43: 389-92.
6. Brochstein JA, Kernan NA, Groshen S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987;317:1618-24.
7. Gluckman E. Current status of bone marrow transplantation for severe aplastic anemia: a preliminary report from the international bone marrow transplant registry. Transplant Proc 1987;19:2597-9.
8. Armitage JO. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989;73:1749-58.
9. Lernarsky C, Kolm DB, Weinberg KI, et al. Bone marrow transplantation for genetic disease. Hematol Oncol Clin North Am 1990;4(3):589-602.
10. Bortin M, Horowitz M, Rimm A. Increasing utilization of allogeneic bone marrow transplantation. Ann Intern Med 1992;116:505-12.
11. Champlin RE, Gale RP. The early complication of bone marrow transplantation. Semin Hematol 1984;21(2): 101-8.
12. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after bone marrow transplantation for leukemia. N Engl J Med 1986;314:729-35.
13. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic bone marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80:1838-45.
14. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse and survival after marrow transplantation for patients with leukemia and lymphoma. Hum Immunol 1990;29:79-91.
15. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987;67:397-406.
16. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991;51(2):443-7.
17. Beatty PG. Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol 1992;19(3, suppl 7):13-19.
18. Herve P, Cahn JY, Beatty PG. Graft-versus-host-disease after bone marrow transplantation from donors other than HLA-identical siblings. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-versus-host disease. New York: Dekker, 1990:425-54.
19. Martin PJ, Schoch G, Fischer L, et al. A retrospective analysis of therapy for acute graft-versus-host-disease: initial treatment. Blood 1990;76:1464-72.
20. Martin PJ, Schoch G, Fischer L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1990;77:1821-8.
21. Weisdorf D, Haake E, Blazar B, et al. Treatment of moderate/severe acute GvHD after allogeneic BMT: an analysis of clinical risk features and outcome. Blood 1990;75:1024.
22. Henslee-Downey PJ. Treatment of acute graft-versus-host-disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-versus-host disease. New York: Dekker, 1990:487-97.
23. Vogelsang GB, Wagner JE. Graft-versus-host disease. Hematol Oncol Clin North Am 1990;4(3):625-39.
24. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324(10):667-74.
25. Deeg, HJ. Graft-versus-host disease: host and donor view. Semin Hematol 1993;30(4, suppl 4): 110-18.
26. Pietryga D. Prevention and treatment of acute graft-versus-host disease. Am J Pediatr Hematol Oncol 1993;15(1):28-48.
27. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow form HLA-matched sibling donors. Transplantation 1974;18(4): 295-304.
28. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975;292(16):832-43, 895-902.
29. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80(12):2964-8.
30. Chao NJ. Graft versus host disease following allogeneic bone marrow transplantation. Curr Opin Immunol 1992;4:571-6.
31. Jadus MR, Wepsie HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992;10:1-14
32. Korngold R. Biology of grafl-vs-host disease. Am J Pediatr Hematol Oncol 1993;15(1):18-27.
33. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993;5:794-9.
34. Krensky AM, Weiss A, Crabtree G, et al. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990;322:510-17.
35. Weiss A, Imboden JB. Cell surface molecules and early events involved in human T lymphocyte activation. Adv Immunol 1987;41:1-38.
36. Stepkowski SM. Transplantation immunobiology: an update. Surg Clin North Am 1994;74(5):991-1013.
37. Theobald M, Nierle T, Bunjes D, et al. Host-specific interleukin-2 secreting donor T-cell precursors as predictor of acute-graft-versus-host in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992;327: 1613-17.
38. Rowbottom AW, Riches PG, Downie C, et al. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993;12:635-41.
39. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 1990;75:1011.
40. Martin PJ, Remlinger K, Hansen JA, et al. Murine monoclonal anti-T cell antibodies for treatment of refractory acute graft-versus-host disease. Transplant Proc 1984;16(6):1494-5.
41. Remlinger K, Martin PJ, Hansen JA, et al. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. Hum Immunol 1984;9:21-35.
42. Martin PJ, Hansen JA, Anasetti C, et al. Treatment of acute graft-versus-host disease with anti-CD-3 monoclonal antibody. Am J Kidney Dis 1988;11(2):149-52.
43. Morgan G, Strobel S, Hale G, et al. Treatment of acute GVHD with an anti-CD7 monoclonal antibody (Campath-2). Bone Marrow Transplant 1987;1(suppl 2):167.
44. Herve P, Wijdenes J, Bergerat JP, et al. Treatment of acute graft-versus-host disease with monoclonal antibody to IL-2 receptor. Lancet 1988;2:1072-3.
45. Blomquist MD, Boggards M, Hanson ICG, et al. Monoclonal anti-T cell (T12) antibody treatment of graft-versus-host disease in severe combined immunodeficiency: targeting of antibody and activation of complement on CD8+ cytotoxic T cell surfaces. J Allergy Clin Immunol 1991;87:1029-33.
46. Anasetti C, Martin PJ, Storb R, et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992;54(5):844-51.
47. Endo Y, Tsurugi K. RNA N-glycosidase activity of ricin A chain. J Biol Chem 1987;262:8128-30.
48. Kernan NA, Knowles RW, Burnes MJ, et al. Specific inhibition of in vitro lymphocyte transformation by anti-pan T cell (gp67) ricin A chain immunotoxin. J Immunol 1984;133:137-46.
49. Kernan NA, Byers V, Scannon PJ, et al. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA 1988;259(21):3154-7.
50. Byers VS, Henslee PJ, Kernan NA, et al. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990;75(7): 1426-32.
51. Lomem PL, Stewart KK, Saks SR, et al. Safety and efficacy of h65-rta in the treatment of steroid-resistant acute graft-versus-host disease after allogeneic bone marrow transplantation [abstr]. Blood 1991;78(10, suppl 1):230a.
52. Gluckman E, Morizet J, Devergie A, et al. Treatment of corticosteroid resistant acute graft versus host disease (gvhd) with a CD8 monoclonal antibody [abstr]. Blood 1988;72:389a.
53. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985;65(6):1325-34.
54. LeMaistre CF. The interleukin-2 receptor as a potential target in therapy of graft-vs-host disease. In: Champlin RE, Gale RP, eds. New strategies in bone marrow transplantation, vol 137. New York: Wiley-Liss, 1991:295-301.
55. Minami Y, Kono T, Miyazaki T, et al The IL-2 receptor complex:. Its structure, function, and target genes. Annu Rev Immunol 1993;11:245-68.
56. Strom TB, Kelley VR, Murphy JR, et al. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu Rev Med 1993;44:343-53.
57. Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murin anti-IL-2 receptor antibody 2A3 for the treatment of acute graft-versus-host disease. Transplantation 1990;50(1):49-54.
58. Herve P, Wijdenes J, Berderat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990;75(4):1017-23.
59. Tiley C, Powles R, Teo CP, et al. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor. Bone Marrow Transplant 1991;7(suppl 2):151
60. Cuthbert RJG, Phillips GL, Barneet MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992;10:451-5.
61. Herbelin C, Stephan JL, Donadieu J, et al. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow. Bone Marrow Transplant 1994;13:563-9.
62. Hertenetein B, Stefanic M, Sandherr M, et al. Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT 563). Transplant Proc 1994;26(6):3114-16.
63. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84(4):1320-7.
64. Takahashi H, Okazaki H, Terasaki PI, et al. Reversal of transplant rejection by monoclonal antiblast antibody. Lancet 1983;2:1155-8.
65. Benaim E, Heslop HE, Brenner MK, et al. Activity of monoclonal antibody CBL1 in corticosteroid resistant acute graft versus host disease [abstr]. Blood 1994;84:540a.
66. Stoppa AM, Maraninchi D, Biaise D, et al. Anti-LFA-1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease. Transplant Int 1991;4:3-7.
67. Rosenblaum MG, Donate NJ. Tumor necrosis factor alpha: a multifaceted peptide hormone. Crit Rev Immunol 1989;9:21-44.
68. Piguet PF, Grau GE, Allet B, et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987;166:1280-9.
69. Irle C, Salamin AF, Bacigalupo A, et al. Serum TNF levels during graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1988;1(suppl 3):127.
70. Symington FW, Sullivan Peje M, Chen AB, et al. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation 1990;50:518-20.
71. Piguet PF. Tumor necrosis factor and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-versus-host disease. New York: Dekker, 1990:255.
72. Herve P, Flesch M, Tiberghien P, et al. Phase I-II of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992;79(12):3362-8.
73. Herve P, Tiberghien P, Racadot E, et al. Prevention and treatment of acute GvHD - new modalities. Bone Marrow Transplant 1993;11(suppl 1):103-6.
74. Robinet E, Pico JL, Ibrahim A, et al. Lack of correlation between serum levels and receptor expression of TNF alpha and graft versus host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1991;7(suppl 2):148.
75. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269(14): 1829-35.
76. Kenadra J, Barrett AJ, Lucas C, et al. Response of graft-versus-host disease to high dose of methylprednisolone. Clin Lab Haematol 1981;3:19.
77. Kanajia MD, Anagnoston AA, Zander AR, et al. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation. Transplantation 1984;37(3):246-9.
78. Norman DJ. Antilymphocyte antibody in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol 1992;12(4):315-24.
79. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994;12(7):1497-1515.
80. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized trial of an anti-interleukin 2 receptor monoclonal antibody (33B3.1) versus rabbit antithymocyte globulin (ATG) in prophylaxis of early rejection in human renal transplantation. N Engl J Med 1990;322:1175.
81. Butturini A, Gale RP. Clinical trials of t-cell depletion: current controversies, future directions. In: Gale RP, Champlin RE, eds. Bone marrow transplantation: current controversies. UCLA symposium in molecular and cellular biology, vol 91. New York: Liss, 1988:495-509.